蔚流生物科技股份有限公司
Update：2026/03/06
Industries
Main Industry
Biotechnology
Main Product/Service
Fluidiconic Biotechnology develops tumor microenvironment chips and culture analysis platforms to support faster and more accurate anticancer drug development. Its TMoC series simulates molecular gradients from blood vessels to the tumor core, preserving tumor genetics and drug responses. Combined with the MedSelect platform and BioVision software, the system enables high-throughput dynamic culture, automated imaging, and visualized analysis, while the BioLab platform provides customized chip integration and ODM services for R&D teams.
Founded Year
2025
Unified Business No.
28115622
Status
Active
Number of Employees
10
Total Paid-in
Capital
37,400,000 (NT$)
Location of Company
Taiwan
, Hsinchu City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Fluidiconic Biotechnology, originating from National Tsing Hua University, focuses on developing the next-generation anticancer drug evaluation platform, MedSelect. Using microfluidic chips for dynamic 3D culture, MedSelect simulates the real tumor microenvironment, aiming to address the high cost, low accuracy, and ethical concerns of traditional animal experiments. The core technology has been published in international journals and recognized with the National Innovation Award and the Boehringer Ingelheim Unicorn Award. The team comprises experts in chemical engineering, biomedical science, microfluidics, and operations management, specializing in tumor microenvironment simulation and immuno-pharmacology analysis. By combining academic research strength with commercial implementation experience, the team is committed to becoming a benchmark in preclinical cancer efficacy validation.
